logo-loader

OKYO Pharma appoints contract research specialist to help advance dry eye treatment

Published: 07:45 29 Jun 2021 BST

Okyo Pharma Ltd -

OKYO Pharma Limited (LON:OKYO; OTCQB:EMMLF) said it retained the services of Ora Inc, the ophthalmology contract research organisation, to “guide product development and regulatory strategy” for OK-101, OKYO’s treatment of dry eye.

The company said the appointment was another step towards filing an investigational new drug (IND) application for the discovery.

OK-101 has been designed to combat washout from the eye through the inclusion of a lipid 'anchor' within the candidate drug molecule to “enhance the residence” time of OK-101 on the ocular surface.

"We are eager to complete IND-enabling studies on OK-101 and move it forward into the clinic as we believe the drug's novel chemical composition, designed as a lipidated stable peptide, offers a new approach to the treatment of DED," said OKYO chief executive Gary Jacob.

"We are especially pleased and excited to be working with Ora as we move forward towards an IND filing."

OKYO Pharma reaches milestone with first patient screening for dry eye...

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) CEO Gary Jacob tells Proactive's Stephen Gunnion that the first patient has been screened for the phase II trial of OK-101, a treatment for dry eye disease (DED), marking a significant step for the company. Jacob says the phase II trials aims to...

on 3/5/23